The antihypertensive effects of a telmisartan 80 mg/hydrochlorothiazide (HCTZ) 12.5 mg fixed-dose combination and telmisartan 80 mg monotherapy were compared in patients with a history of mild-to-moderate essential hypertension and inadequate BP control (DBP у90 mm Hg) following 8 weeks of telmisartan monotherapy. At the end of this period, 491 patients (62.9% men; mean age 55.3 years) whose DBP was у90 mm Hg were double-blind randomised to once-daily telmisartan 80 mg/HCTZ 12.5 mg (n ‫؍‬ 246) or telmisartan 80 mg (n ‫؍‬ 245). Trough (24 h post-dose) clinic BP was measured after 4 and 8 weeks of double-blind therapy. At the end of double-blind treatment, patients receiving telmisartan 80 mg/HCTZ 12.5 mg had significant additional decrements in clinic SBP/DBP over telmisartan 80 mg of ؊5.7/؊3.1 mm Hg (P Ͻ 0.01). Most of the additional
Introduction
It is of some disappointment that the deficiencies in awareness, treatment and control of high blood pressure in the community identified some 30 years ago are still observed today. [1] [2] [3] [4] [5] While increasingly stringent blood pressure targets may partially explain the continuing shortfalls in hypertension control, 4, 6 other factors also play an important role.
Many primary care physicians are reluctant to use multiple agents in patients not responding adequately to antihypertensive monotherapy. 7 This behaviour probably contributes substantially to the low overall rate of hypertension control in the community, since a significant proportion of patients do not attain target blood pressure on a single agent. 4, 6, 8, 9 Well-tolerated fixed-dose combination therapies are becoming available that should facilitate the attainment of blood pressure targets early in the treatment process.
Telmisartan, an angiotensin II type 1 (AT 1 ) receptor antagonist, is an effective once-daily antihypertensive agent that provides full 24-h blood pressure control and has an adverse event profile comparable to placebo. [10] [11] [12] [13] [14] [15] Hydrochlorothiazide (HCTZ) is a benzothiadiazide diuretic; these agents lower blood pressure through alteration of the sodium balance. HCTZ also augments the therapeutic response to some other classes of antihypertensive agents. For example, activation of the renin-angiotensin-aldosterone system (RAAS) by HCTZ amplifies the effects of agents acting through blockade of this pathway, including AT 1 receptor antagonists. [16] [17] [18] [19] [20] [21] Combination of HCTZ with agents acting on the RAAS also has the potential to ameliorate the potassium depletion commonly associated with thiazide diuretic therapy. 17, 22, 23 A fixed-dose combination of telmisartan 80 mg/HCTZ 12.5 mg has been developed for the treatment of patients with mild-to-moderate hypertension. The doses selected were based on a previous dose-response study showing that telmisartan 80 mg has greater antihypertensive efficacy than telmisartan 40 mg, but further dose increase confers no extra therapeutic benefit. 10, 13 In contrast, HCTZ addon to telmisartan produces incremental reductions in both systolic (SBP) and diastolic blood pressure (DBP). 16 Therefore, for patients not attaining target blood pressure on telmisartan 80 mg, one of the next logical steps could be the addition of HCTZ.
This supposition was examined in the current study. The objective was to compare the antihypertensive efficacy and safety of the telmisartan 80 mg/HCTZ 12.5 mg fixed-dose combination with telmisartan 80 mg monotherapy in patients with mild-to-moderate hypertension who were not adequately controlled on telmisartan 40 or 80 mg alone.
Materials and methods

Patient selection
Male and female patients, aged 18-80 years, with a history of mild-to-moderate essential hypertension (DBP 95-114 mm Hg and SBP 140-200 mm Hg) at entry and inadequate blood pressure control (DBP у90 mm Hg) following 8 weeks of telmisartan monotherapy were eligible to participate in this trial. Excluded were patients taking more than three antihypertensive drugs at screening, and those with secondary hypertension, uncontrolled type 1 diabetes mellitus or significant cardiovascular, cerebrovascular, renal or hepatic disease. Patients with clinically relevant laboratory abnormalities, a history of angiooedema, pregnant women, and women of childbearing age who were not using an adequate method of contraception were also excluded.
The study was approved by the Institutional Review Board of each site participating in the trial, and all patients gave written informed consent prior to enrolment.
Study design
This multicentre, prospective, randomised, doubleblind, parallel-group study was conducted at 15 sites in Canada. A filter design was chosen to select for randomisation only those patients who did not normalise their blood pressure on telmisartan 80 mg, thereby allowing evaluation of the addition of HCTZ to a background of telmisartan monotherapy.
An outline of the study design is depicted in Figure 1 . After a screening/washout period of 3-10 days, eligible patients entered an 8-week open-label filter period, during which they received telmisartan 40 mg once daily for the first 4 weeks. At the end of this 4-week period, patients responding to telmisartan 40 mg (seated DBP Ͻ90 mm Hg) were withdrawn; non-responders were titrated to once-daily telmisartan 80 mg for a further 4 weeks of open-label therapy. Patients whose DBP remained у90 mm Hg at the end of this period were then randomly allocated to 8 weeks of once-daily, double-blind treatment with either telmisartan 80 mg or a fixed-dose combination of telmisartan 80 mg/HCTZ 12.5 mg.
A double-dummy technique was used to ensure blinding, with each patient taking two tablets of study medication per day at approximately 08.00. On the days of a clinic visit, study medication was administered after blood pressure measurements had been made. Treatment with other drugs that could interfere with the evaluation of efficacy and tolerability was prohibited throughout the study. Compliance was assessed by counting pills returned at each clinic visit.
Efficacy evaluations
Seated and standing blood pressure were measured at trough (24 h after the previous dose) at each clinic visit by manual cuff sphygmomanometry, according to the criteria of the American Society of Hypertension. 24 Following a 5-min period of rest in a sitting position, three blood pressure measurements were taken 2 min apart. After the third reading, the patient stood up and blood pressure was measured immediately. Two additional standing readings were taken at intervals of 2 min. The means of the three seated and standing SBP and DBP measurements were used in the efficacy analyses. Seated and standing pulse rates were assessed between the second and third blood pressure measurements.
The primary efficacy parameter was the reduction in mean seated DBP from baseline (randomisation, visit 4) to the end of the 8-week double-blind study period with telmisartan 80 mg/HCTZ 12.5 mg and telmisartan 80 mg monotherapy. A difference of 3.0 mm Hg or more between treatment groups was considered to be clinically significant. Selection of this criterion was based on previous studies using angiotensin receptor blockers. Other efficacy variables included changes from baseline to study end in mean seated SBP, and mean standing SBP and DBP. Blood pressure measurements made after 4 weeks of double-blind treatment (visit 5) allowed description of the time course of the antihypertensive response.
Responder rates were also calculated at the end of the 8-week double-blind treatment period, based on mean seated blood pressure measurements. A normalised blood pressure response was defined as SBP Ͻ140 mm Hg and DBP Ͻ90 mm Hg, an optimal blood pressure response was defined as SBP Ͻ130 mm Hg and DBP Ͻ85 mm Hg, and a DBP response was defined as DBP Ͻ90 mm Hg.
Safety assessments
Adverse events and concomitant treatments were monitored throughout the entire study period. The onset, duration, intensity, treatment required, outcome, action taken and relationship to study medication were recorded for all adverse events reported. Additional safety assessments included changes between baseline and study end in physical examination, 12-lead ECG, laboratory parameters and pulse rate. Any cases of orthostatic hypotension were also noted. This was considered clinically relevant if the drop in blood pressure when the patient moved from a seated to a standing position was у10 mm Hg more than the maximal decrease observed during the open-label, titration run-in phase.
Statistical analyses
The primary objective of this study was to demonstrate that a fixed-dose combination of telmisartan 80 mg/HCTZ 12.5 mg is superior to telmisartan 80 mg monotherapy in lowering seated DBP after 8 weeks of treatment in patients not achieving goal DBP (Ͻ90 mm Hg) on telmisartan alone. In cases where blood pressure measurements were not available for Week 8, a last observation carried forward method was used. It was estimated that approximately 1200 patients would have to be enrolled and 432 randomised to detect a treatment difference of at least 3.0 mm Hg in the reduction from baseline in trough seated DBP with a power of 90% (two-sided, ␣ ϭ 0.05). The
Journal of Human Hypertension standard deviation was assumed to be about 9 mm Hg. The primary analysis was conducted on the intent-to-treat population, consisting of all randomised patients who took at least one dose of doubleblind medication and for whom a baseline measurement and at least one post-randomisation measurement were available.
Differences between treatment groups in the changes from baseline in mean seated and standing SBP and DBP were assessed using an analysis of covariance (ANCOVA) model with treatment and centre as factors and baseline blood pressure measurement as covariate. Responder rates were expressed as percentages and compared by the Mantel-Haenszel test. Significant differences in the incidence of adverse events were identified using Fisher's exact test.
Results
Patients
Of the 781 patients enrolled in the study, 491 (62.9%) fulfilled all inclusion criteria and were randomised to 8 weeks of double-blind treatment with telmisartan 80 mg/HCTZ 12.5 mg (n ϭ 246) or telmisartan 80 mg (n ϭ 245). No relevant differences were noted between the two treatment groups with respect to age, gender, race, hypertension duration, body mass index, blood pressure and pulse rate at baseline (Table 1) .
A total of 475 patients (96.7%) completed the study (240 on telmisartan 80 mg/HCTZ 12.5 mg; 235 on telmisartan 80 mg). There were 16 discontinuations: six patients discontinued for adverse events, three for lack of efficacy, one for non-compliance, two withdrew consent, three were lost to follow-up and one patient with an enlarged axillary node at screening was withdrawn after Hodgkin's disease was diagnosed. The reasons for discontinuation did not differ significantly between the two treatment groups. Compliance to treatment was 98.9% among telmisartan 80 mg/HCTZ 12.5 mg-treated patients and 98.8% among telmisartan 80 mg-treated patients.
Efficacy
Results are presented here for analysis of the intentto-treat population (n ϭ 491). Mean seated DBP was reduced from baseline by 8.0 mm Hg with the telmisartan 80 mg/HCTZ 12.5 mg fixed-dose combination and by 4.9 mm Hg with telmisartan 80 mg ( Table 2) . This additional 3.1 mm Hg reduction in mean seated DBP with telmisartan 80 mg/HCTZ 12.5 mg over telmisartan 80 mg was statistically significant (P Ͻ 0.01). The trial was designed with the assumption that a difference between treatments of у3.0 mm Hg in mean seated DBP would be clinically rel- Table 2) .
Similar patterns of results were observed for the decreases in mean standing SBP and DBP, with the telmisartan 80 mg/HCTZ 12.5 mg fixed-dose combination producing statistically significant additional SBP/DBP reductions of 5.8/3.2 mm Hg over telmisartan 80 mg monotherapy (P Ͻ 0.01) ( Table 2) . Neither treatment regimen influenced seated or standing pulse rates.
The blood pressure response to treatment over time was examined in a subset of evaluable patients who completed all three scheduled clinic visits (visits 4 -6) during the 8-week double-blind treatment period. The evaluable population comprised 465 of the 491 patients randomised (94.7%). This analysis demonstrated that most of the additional effect on SBP and DBP with telmisartan 80 mg/HCTZ 12.5 mg vs telmisartan 80 mg was apparent -and statistically significant (P Ͻ 0.01) -after 4 weeks of treatment (Figure 2 ). Smaller further reductions in SBP and DBP were observed between weeks 4 and 8 of the double-blind treatment period.
Responder rates
Response rates were consistently higher with the telmisartan 80 mg/HCTZ 12.5 mg combination than with telmisartan 80 mg monotherapy. Blood pressure was normalised in 41.5% of patients on telmisartan 80 mg/HCTZ 12.5 mg and 26.1% on telmisartan 80 mg (P Ͻ 0.05). In addition, an optimal blood pressure response was achieved by 19.5% of patients on telmisartan 80 mg/HCTZ 12.5 mg and 9.4% on telmisartan 80 mg (P Ͻ 0.05), and a DBP response was achieved by 52.4% of patients on telmisartan 80 mg/HCTZ 12.5 mg and 35.5% on telmisartan 80 mg (P Ͻ 0.05). 
Safety
Both study treatments were well tolerated. Of the 491 patients randomised, 89 (36.2%) on telmisartan 80 mg/HCTZ 12.5 mg and 97 (39.6%) on telmisartan 80 mg reported an adverse event during doubleblind treatment, the majority of which were mild and transient. The adverse events reported most frequently are presented in Table 3 . Whilst oedema was more common among patients receiving telmisartan 80 mg, there were more reports of diarrhoea and bronchitis in the telmisartan 80 mg/HCTZ 12.5 mg treatment group. However, these differences are unlikely to be clinically important. Three patients reported serious adverse events during double-blind treatment, one receiving telmisartan 80 mg/HCTZ 12.5 mg (renal calculus) and two receiving telmisartan 80 mg (syncope, chest pain). These adverse events were not regarded as drugrelated, and none of the patients required withdrawal. The percentages of patients with drugrelated adverse events were similar between the two treatment groups: 9.3% (n ϭ 23) for telmisartan 80 mg/HCTZ 12.5 mg and 7.8% (n ϭ 19) for telmisartan 80 mg. These were of varying types, with no specific correlation between any single adverse event and treatment.
Similar proportions of patients in the telmisartan 80 mg/HCTZ 12.5 mg and telmisartan 80 mg groups experienced positional changes in DBP (2.8% vs 2.4%), SBP (4.9% vs 3.3%) and pulse rate (3.2% vs 2.4%), and there were no clinically relevant changes in physical examination, ECG findings or laboratory parameters.
Discussion
This study has shown that the antihypertensive efficacy of a fixed-dose combination of telmisartan 80 mg/HCTZ 12.5 mg is clinically and statistically superior to telmisartan 80 mg monotherapy in patients inadequately controlled (DBP у90 mm Hg) on telmisartan 40-80 mg alone. The telmisartan 80 mg/HCTZ 12.5 mg fixed-dose combination produced additional reductions in clinic seated SBP/DBP over telmisartan 80 mg of 5.7/3.1 mm Hg (P Ͻ 0.01), with most of the incremental effect occurring during the first 4 weeks of double-blind treatment. Analyses of standing blood pressure yielded similar results. Safety assessments also indicated that both treatments were well tolerated.
An 8-week, two-step titration, filter study design was applied to select a group of patients with mildto-moderate hypertension who were uncontrolled on telmisartan monotherapy, allowing direct evaluation of the therapeutic benefit of HCTZ add-on treatment. The filter design also mimics the stepped care approach to hypertension management that is usually applied in clinical practice: to attain target blood pressure, patients are likely to be started on telmisartan 40 mg, titrated to telmisartan 80 mg, and then have HCTZ added. The screening/washout period of only 3-10 days between switching therapies is also more likely to reflect actual clinical experience.
Results from several epidemiological studies suggest that SBP may be even more important as a risk factor than DBP, implying that there should be a greater emphasis on SBP in the diagnosis and management of hypertension. [25] [26] [27] [28] For example, in middle-aged and older persons, SBP has been shown to be related even more strongly to risk than DBP -at any given DBP level, higher SBP correlates with greater cardiovascular disease risk and curtailment of life expectancy. 25 Nevertheless, treatment strategies have tended to focus on lowering DBP, because it is more easily controlled than SBP. With this in mind, the findings of the current study are particularly important. The telmisartan 80 mg/ HCTZ 12.5 mg fixed-dose combination reduced SBP to a mean of 135.8 mm Hg, and normalised both SBP (Ͻ140 mm Hg) and DBP (Ͻ90 mm Hg) in 41.5% of patients. These results are even more impressive considering the filter design of the trial in that they do not take into account those patients whose blood pressure was normalised on telmisartan 80 mg during the 8-week open-label treatment period.
Experimental studies have shown that angiotensin II causes proliferation of vascular smooth muscle cells and increases the media:lumen ratio and the media cross-sectional area of mesenteric small arteries.
29 Such vessel remodelling itself contributes to the maintenance of high blood pressure by increasing the peripheral resistance. Thus, normalisation of vascular structure should be an important goal of antihypertensive therapy. Treatment with an AT 1 receptor antagonist, but not a ␤-blocker, significantly reduced the media:lumen ratio of resistance arteries from patients with essential hypertension despite similar antihypertensive effects. 30 One may speculate that the further reduction in blood pressure observed between weeks 4 and 8 with telmisartan in the current study (and reported previously) 15 may be due to a progressive reversal of angiotensin II-induced vascular remodelling and a resultant decrease in peripheral resistance.
The findings of the present investigation are in keeping with those from a trial of factorial design which evaluated the antihypertensive efficacy of two telmisartan/HCTZ combinations (telmisartan 40 mg/HCTZ 12.5 mg and telmisartan 80 mg/HCTZ 12.5 mg relative to their individual components in patients with mild-to-moderate hypertension. 16 In that study, concomitant treatment with telmisartan 80 mg and HCTZ 12.5 mg decreased supine trough SBP/DBP by an additional 8.5/3.4 mm Hg over telmisartan 80 mg monotherapy. However, the patients enrolled by McGill et al 16 were all-comers and not filtered for their failure to respond adequately to telmisartan monotherapy. This disparity in patient selection criteria accounts for the differences between the two studies in the proportions of patients achieving a DBP response (Ͻ90 mm Hg) with telmisartan 80 mg/HCTZ 12.5 mg: 52.4% in the current trial compared with 64% in that reported by McGill et al. 16 A study similar in design to the present one compared combinations of valsartan plus HCTZ with valsartan monotherapy in patients who failed to respond adequately to valsartan alone. 20 Treatment with valsartan 80 mg/HCTZ 12.5 mg had a therapeutic advantage of 3.2 mm Hg on DBP and 5.9 mm Hg on SBP over valsartan 80 mg monotherapy. Response rates were also comparable to those reported with the telmisartan/HCTZ fixed-dose combination in the present study. It should be noted, however, that the criterion for DBP control in the valsartan study (DBP Ͻ95 mm Hg) was less stringent than that employed in the current trial (DBP Ͻ90 mm Hg).
That 62.9% of the patients enrolled in the openlabel period were inadequately controlled on telmisartan 40 or 80 mg and entered the double-blind phase of the study reflects some bias in patient preselection. Investigators were advised to favour the enrolment of patients taking more than one antihypertensive agent or those who were unresponsive to previous treatment with angiotensin-converting enzyme inhibitors or other AT 1 receptor antagonists. This policy was intended to maximise the numbers of patients who would not reach target blood pressure on telmisartan monotherapy and would thus be eligible for entry into the double-blind phase of the trial. It is also worthy of note that hypertension had been present for over 5 years in more than half of the patients randomised (57.8%).
Both treatments were well tolerated, with adverse events being mainly mild and transient. These safety data confirm the excellent safety profile reported previously with telmisartan either alone 10 or in combination with HCTZ 12.5 mg. 16 Such findings highlight one of the benefits of low-dose combination therapy in that it provides effective blood pressure control whilst minimising the occurrence of dosedependent side effects.
No clinically meaningful changes were observed in any of the laboratory parameters assessed in the current study. HCTZ alone has the potential to cause potassium depletion, which is believed to result from reflex activation of the RAAS following a reduction in plasma volume. Although slight increases in serum potassium have been reported with telmisartan in placebo-controlled trials (amounting to a median increase of 0.1 mEq/L; Boehringer Ingelheim, data on file), no cases of hyperkalaemia have occurred in the clinical programme. Interestingly, in the telmisartan/HCTZ factorial study by McGill et al, 16 combinations of telmisartan and HCTZ tended to offset the differential drug effects on serum potassium, suggesting that telmisartan may actually attenuate HCTZ-induced hypokalaemia. A similar corrective effect on serum potassium levels has also been observed when irbesartan, another AT 1 receptor antagonist, is co-administered with HCTZ. 17 In conclusion, our study has shown that oncedaily treatment with a fixed-dose combination of telmisartan 80 mg/HCTZ 12.5 mg offers superior efficacy to telmisartan 80 mg in patients with mild-tomoderate hypertension uncontrolled on telmisartan alone. This fixed-dose combination is also well tolerated.
